Anti-sortilin antibodies, uses and methods for treatment
The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful in correcting a deficient level of progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
1. An antibody, or an antigen-binding fragment thereof, capable of binding specifically to Sortilin, wherein the antibody or antigen-binding fragment thereof comprises:
a. a light chain variable domain L-CDR1 comprising SEQ ID NO:145;
b. a light chain variable domain L-CDR 2 comprising SEQ ID NO:146;
c. a light chain variable domain L-CDR 3 comprising SEQ ID NO:147;
d. a heavy chain variable domain H-CDR 1 comprising SEQ ID NO:148;
e. a heavy chain variable domain H-CDR 2 comprising SEQ ID NO:149; and
f. a heavy chain variable domain H-CDR 3 comprising SEQ ID NO:150.
2. The antibody, or antigen-binding fragment thereof, according to claim 1 , wherein the antigen-binding fragment is selected from the group consisting of: an Fv fragment, a single chain Fv (scFv), a disulfide-bonded Fv, a Fab fragment, a Fab′ fragment, and a F(ab)2 fragment.
3. The antibody, or antigen-binding fragment thereof, according to claim 1 , wherein said antibody or antigen-binding fragment thereof binds to said D Region of Sortilin at a site defined by SEQ ID NO:170.
4. The antibody, or antigen-binding fragment thereof, according to claim 1 , wherein the antibody is a human, humanized, recombinant or chimeric antibody.
5. The antibody, or antigen-binding fragment thereof, according to claim 1 , comprising:
a light chain variable domain comprising SEQ ID NO:151 and a heavy chain variable domain comprising SEQ ID NO:152.
6. A pharmaceutical composition comprising the antibody, or the antigen-binding fragment thereof, as defined in claim 1 , and a pharmaceutically acceptable carrier.
7. A pharmaceutical composition comprising the antibody, or the antigen-binding fragment thereof, as defined in claim 5 , and a pharmaceutically acceptable carrier.